Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 760 JPY 2.04% Market Closed
Market Cap: 133.8B JPY
Have any thoughts about
Torii Pharmaceutical Co Ltd?
Write Note

Torii Pharmaceutical Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Torii Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Income from Continuing Operations
ÂĄ5.3B
CAGR 3-Years
18%
CAGR 5-Years
-27%
CAGR 10-Years
6%
Takeda Pharmaceutical Co Ltd
TSE:4502
Income from Continuing Operations
ÂĄ290.2B
CAGR 3-Years
-15%
CAGR 5-Years
28%
CAGR 10-Years
12%
Daiichi Sankyo Co Ltd
TSE:4568
Income from Continuing Operations
ÂĄ250.7B
CAGR 3-Years
42%
CAGR 5-Years
17%
CAGR 10-Years
14%
Otsuka Holdings Co Ltd
TSE:4578
Income from Continuing Operations
ÂĄ155.2B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Income from Continuing Operations
ÂĄ387B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
22%
Astellas Pharma Inc
TSE:4503
Income from Continuing Operations
ÂĄ54.6B
CAGR 3-Years
-18%
CAGR 5-Years
-25%
CAGR 10-Years
-6%
No Stocks Found

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
133.8B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
3 379.07 JPY
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Torii Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
5.3B JPY

Based on the financial report for Sep 30, 2024, Torii Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 5.3B JPY.

What is Torii Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
6%

Over the last year, the Income from Continuing Operations growth was 53%. The average annual Income from Continuing Operations growth rates for Torii Pharmaceutical Co Ltd have been 18% over the past three years , -27% over the past five years , and 6% over the past ten years .

Back to Top